![]() NEW YORK, November 02, 2021-( BUSINESS WIRE)-Pfizer Inc. Will Highlight Promising New Data on Multiple Novel Compounds in I&I, as Well as Clinical and Regulatory Updates for Gene Therapy and COVID-19 Development Programs on Conference Call ![]() Raises Midpoint of Guidance for Adjusted Diluted EPS (3) Excluding Comirnaty (1) to a Range of $2.60 to $2.65 Raises Full-Year 2021 Guidance (4) for Revenues to a Range of $81.0 to $82.0 Billion and Adjusted Diluted EPS (3) to a Range of $4.13 to $4.18, Reflecting 94% and 84% Year-Over-Year Growth at the Midpoints, RespectivelyĪnticipates 2021 Revenues of Approximately $36 Billion for Comirnaty (1), Reflecting 2.3 Billion Doses Expected to be Delivered in Fiscal 2021 Third-Quarter 2021 Reported Diluted EPS (2) of $1.42, Adjusted Diluted EPS (3) of $1.34 Third-Quarter 2021 Revenues of $24.1 Billion, Reflecting 130% Operational Growth Excluding Comirnaty (1), Revenues Grew 7% Operationally to $11.1 Billion
0 Comments
Leave a Reply. |